FDA approves Roche’s leukemia drug combo Venclexta plus Gazyva

This article was originally published here

Venclexta/Venclyxto is a first-in-class targeted medicine that will selectively bind and restrict the B-cell lymphoma-2 (BCL-2) protein, while Gazyva/Gazyvaro is an engineered monoclonal antibody that will attach to

The post FDA approves Roche’s leukemia drug combo Venclexta plus Gazyva appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply